These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17961098)

  • 1. Drotrecogin alpha (activated): the treatment for severe sepsis?
    Vincent JL
    Expert Opin Biol Ther; 2007 Nov; 7(11):1763-77. PubMed ID: 17961098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa: a new approach in the treatment of severe sepsis.
    Vincent JL
    Expert Opin Biol Ther; 2002 Aug; 2(6):659-64. PubMed ID: 12171509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
    McCoy C; Matthews SJ
    Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
    Pastores SM
    Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
    Yan SB; Nelson DR
    Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
    Kanji S; Devlin JW; Piekos KA; Racine E
    Pharmacotherapy; 2001 Nov; 21(11):1389-402. PubMed ID: 11714212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Curr Drug Saf; 2007 Sep; 2(3):227-31. PubMed ID: 18690972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human activated protein C in severe sepsis.
    Mann HJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S19-23. PubMed ID: 11885409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
    Rudis MI; Fish DN
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
    Dhainaut JF; Laterre PF; Janes JM; Bernard GR; Artigas A; Bakker J; Riess H; Basson BR; Charpentier J; Utterback BG; Vincent JL;
    Intensive Care Med; 2003 Jun; 29(6):894-903. PubMed ID: 12712239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
    Bernard GR
    Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating severe sepsis with drotrecogin alfa (activated).
    Wyncoll D
    Hosp Med; 2003 Mar; 64(3):168-72. PubMed ID: 12669484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.